Beijing Tiantan Biological Products Corporation Limited Class A

Beijing Tiantan Biological Products Corporation Limited Class A

SSSE:600161
12.02
CNY
-0.11
(-0.91%)
0.48EPS
36.10P/E
24.90BMarket Cap
Apr 27Next Earn

Total Valuation

CNY

As of September 30, 2026, Beijing Tiantan Biological Products Corporation Limited Class A carries a market capitalization of 24.90B, placing it among publicly traded companies globally. Its enterprise value stands at 26.75B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap24.90B
Enterprise Value26.75B

Important Dates

Beijing Tiantan Biological Products Corporation Limited Class A's next confirmed earnings release is scheduled for April 27, 2027.

Earnings Date4/27/2027

Share Statistics

As of September 30, 2026, Beijing Tiantan Biological Products Corporation Limited Class A has 1.98B shares outstanding.

Shares Outstanding1.98B

Valuation Ratios

As of September 30, 2026, Beijing Tiantan Biological Products Corporation Limited Class A trades at a trailing price-to-earnings ratio of 36.10. The price-to-sales ratio is 4.55, and the price-to-book ratio stands at 2.10.

PE Ratio36.10
PS Ratio4.55
PB Ratio2.10
P/TBV Ratio2.54

Enterprise Valuation

As of September 30, 2026, Beijing Tiantan Biological Products Corporation Limited Class A trades at an EV/EBITDA multiple of 21.61 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 4.81 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 21.61 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 26.75B versus a market cap of 24.90B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales4.81
EV / EBITDA21.61
EV / EBIT21.61

Financial Position

As of September 30, 2026, Beijing Tiantan Biological Products Corporation Limited Class A maintains a current ratio of 8.12, meaning it holds 8.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.51, indicating moderate leverage, while an interest coverage ratio of 235.72 demonstrates strong ability to service its debt obligations.

Current Ratio8.12
Quick Ratio1.82
Debt / Equity0.51
Debt / EBITDA0.06
Interest Coverage235.72

Financial Efficiency

CNY

These figures cover the twelve months ended September 30, 2026. The company generates approximately 1.07M in revenue per employee across its workforce of 5,205.00, a quick read on workforce productivity versus industry peers.

Revenue Per Employee1.07M
Employee Count5,205.00

Taxes

CNY

Over the twelve months ended September 30, 2026, Beijing Tiantan Biological Products Corporation Limited Class A recorded 262.57M in income tax expense. That works out to an effective tax rate of 21.42, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 1.23B, leaving 700.14M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax262.57M
Effective Tax Rate21.42

Stock Price Statistics

CNY

As of the close on November 17, 2026, Beijing Tiantan Biological Products Corporation Limited Class A's stock has declined approximately 34.46% over the past 52 weeks. The 50-day moving average sits at 12.37, while the 200-day moving average is 13.65.

52-Week Price Change-34.46%
50-Day Moving Average12.37
200-Day Moving Average13.65

Income Statement

CNY

Over the twelve months ended September 30, 2026, Beijing Tiantan Biological Products Corporation Limited Class A generated 5.56B in revenue and converted that into 700.14M in net income, yielding earnings per share of 0.48. EBITDA reached 1.24B, while operating income came in at 1.27B.

Revenue5.56B
Gross Profit2.11B
Operating Income1.27B
Pretax Income1.23B
Net Income700.14M
EBITDA1.24B
EBIT1.24B
Earnings Per Share (EPS)0.48

Balance Sheet

CNY

As of September 30, 2026, Beijing Tiantan Biological Products Corporation Limited Class A holds 1.90B in cash and equivalents against 79.25M in total debt, resulting in a net debt position of -1.90B. Total book value stands at 11.87B, with working capital of 7.46B providing operational flexibility.

Cash & Cash Equivalents1.90B
Total Debt79.25M
Net Debt-1.90B
Equity (Book Value)11.87B
Book Value Per Share6.00
Working Capital7.46B

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-619.41M

Margins

Over the twelve months ended September 30, 2026, Beijing Tiantan Biological Products Corporation Limited Class A posted a gross margin of 37.97, reflecting its pricing power and cost economics. The operating margin of 22.89 and net profit margin of 12.60 provide insight into operational efficiency.

Gross Margin37.97
Operating Margin22.89
Pretax Margin22.07
Profit Margin12.60
EBITDA Margin22.28

Dividends & Yields

Over the twelve months ended September 30, 2026, Beijing Tiantan Biological Products Corporation Limited Class A paid dividends of 0.00 per share. The dividend payout ratio of 0.02 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 0.16, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Beijing Tiantan Biological Products Corporation Limited Class A shareholders.

Payout Ratio0.02
Shareholder Yield0.16

Stock Splits

Beijing Tiantan Biological Products Corporation Limited Class A's most recent stock split took place on June 20, 2024 with a 5:6 split ratio.

Last Split Date6/20/2024
Split Ratio5:6

Scores

As of September 30, 2026, Beijing Tiantan Biological Products Corporation Limited Class A has an Altman Z-Score of 13.79, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score13.79